Animation commissioned by Myopharm to visualise the mechanism of action (MOA) of TriGlytza ™, a novel combination drug to threat type 2 diabetes.

TriGlytza ™ is a beta-cell centric dual combination drug that proposes to mitigate progressive beta-cell deterioration by reducing levels of pro-inflammatory mediators.

The project was developed during my time at Arterial Design, where I contributed to the modelling, animation and compositing.